DM FMedSci - Awakn Life Chair Officer
| AWKNF Stock | USD 0.08 0 4.17% |
Insider
DM FMedSci is Chair Officer of Awakn Life Sciences
| Web | https://awaknlifesciences.com |
Awakn Life Management Efficiency
The company has return on total asset (ROA) of (0.8162) % which means that it has lost $0.8162 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.84) %, meaning that it generated substantial loss on money invested by shareholders. Awakn Life's management efficiency ratios could be used to measure how well Awakn Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Terrence MD | Arch Therapeutics | 58 | |
| Steven Kates | Arch Therapeutics | N/A | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Annie Lee | Opthea | N/A | |
| Dr MBA | Cellectis SA | 46 | |
| MBA MSc | Antibe Therapeutics | 65 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Christina BBA | Antibe Therapeutics | N/A | |
| Michael Abrams | Arch Therapeutics | 53 | |
| Daniel Yrigoyen | Arch Therapeutics | 53 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| James Goding | Opthea | N/A | |
| MEng CFA | Antibe Therapeutics | N/A | |
| MD MBA | Opthea | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Valerie Cros | Cellectis SA | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Matthew Gall | Iteos Therapeutics | 47 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
Management Performance
| Return On Equity | -2.84 | |||
| Return On Asset | -0.82 |
Awakn Life Sciences Leadership Team
Elected by the shareholders, the Awakn Life's board of directors comprises two types of representatives: Awakn Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Awakn. The board's role is to monitor Awakn Life's management team and ensure that shareholders' interests are well served. Awakn Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Awakn Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Scorsis, Cofounder Chairman | ||
| Gordo Whittaker, Chief Officer | ||
| Shaun McNulty, Chief Board | ||
| Pr Morgan, Head Board | ||
| DM FMedSci, Chair Officer | ||
| James Collins, Chief Officer | ||
| MD FACEP, Regional AS | ||
| MBBS BSc, Head CoFounder | ||
| Anthony Tennyson, President, Cofounder |
Awakn Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Awakn Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.84 | |||
| Return On Asset | -0.82 | |||
| Operating Margin | (8.79) % | |||
| Current Valuation | 6.58 M | |||
| Shares Outstanding | 32.48 M | |||
| Shares Owned By Insiders | 9.92 % | |||
| Shares Owned By Institutions | 8.34 % | |||
| Price To Book | 4.19 X | |||
| Price To Sales | 7.96 X | |||
| Revenue | 236.04 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Awakn OTC Stock
Awakn Life financial ratios help investors to determine whether Awakn OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Awakn with respect to the benefits of owning Awakn Life security.